Ivabradine Biogaran

Ivabradine, the active ingredient in Ivabradine Biogaran, is an If‑channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used to treat chronic stable angina and heart failure with reduced ejection fraction in adult patients who experience symptomatic disease despite optimal therapy.

GNH USA supplies Ivabradine Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution.

Ivabradine is an If‑channel inhibitor used in cardiovascular conditions that benefit from heart‑rate reduction.

- Chronic stable angina: lowers heart rate, which reduces myocardial oxygen demand and consequently decreases the frequency and severity of angina episodes in patients with chronic stable angina. - Heart failure with reduced ejection fraction: decreases heart rate, improving ventricular filling time and cardiac efficiency, thereby alleviating symptoms and potentially reducing hospitalization rates in patients with HFrEF.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 beats/min. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo: especially on standing.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other serious arrhythmias. - Severe hypotension or syncope. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Ivabradine, clinicians should consider several precautionary measures to ensure safe use. - Baseline heart rate assessment: confirm resting heart rate ≥ 60 bpm before starting therapy. - Concomitant bradycardic agents: avoid or adjust dose when used with beta‑blockers, digoxin, or calcium‑channel blockers. - Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction. - Renal impairment: dose adjustment may be required in severe renal failure. - Pregnancy and lactation: safety not established; prescribe only if potential benefit justifies potential risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Ivabradine can interact with other medicines, altering its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole): may markedly increase Ivabradine levels. - Other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive bradycardia. - Concomitant use with other If‑channel blockers: not recommended.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Drugs that prolong QT interval (certain antiarrhythmics): monitor ECG. - Antihypertensives: observe for additive blood pressure lowering.